ETIDIOH - NEW

  Ann Intern Med LALANI HS, DiResta R, Baron RJ, Scales D, et al Addressing Viral Medical Rumors and False or Misleading Information. Ann Intern Med. 2023 Jul 18. doi: 10.7326/M23-1218. PubMed           Abstract available Antimicrob Agents Chemother ZHENG X, You X, Liu Y, Wu B, et al Spatiotemporal dynamics and multiple driving factors of antimicrobial resistance in China during the COVID-19 pandemic (2019-2023): a provincial panel data analysis. Antimicrob Agents Chemother. 2026 Feb 9:e0160025. doi: 10.1128/aac.01600. PubMed           Abstract available Antiviral Res ZHANG T, Wang ZL, Li XY, Luo RH, et al Onvansertib and vilazodone inhibit SARS-CoV-2 replication via suppression of METTL3 RNA-m(6)A enzymatic activity. Antiviral Res. 2026 Feb 19:106376. doi: 10.1016/j.antiviral.2026.106376. PubMed           Abstract available YURGELONIS I, Rai DK, Li Z, Washington ...

  Abstract In the United States, annual influenza vaccination has been recommended for all persons aged ≥6 months , including during the 2025–26 season. Interim influenza vaccine effectiveness (VE) estimates were calculated for patients with acute respiratory illness–associated outpatient visits and hospitalizations from three U.S. respiratory virus VE networks during the 2025–26 influenza season, using a test-negative case-control design . Among children and adolescents aged <18 years, VE was 38%–41% against influenza outpatient visits and 41% against influenza-associated hospitalization . Among adults aged ≥18 years, VE was 22%–34% against influenza outpatient visits and 30% against influenza-associated hospitalization . Among children and adolescents , VE against influenza A ranged from 37% (against outpatient visits) to 42% (against hospitalization) across settings; among adults , VE against influenza A ranged from 30% (against hospitalization) to 34% (against outpatient vis...

  {Excerpt} (...) Results NAb geometric mean titers against H1N1 WI/22, H3N2 BA/22, H3N2 CR/23, H3N2-K BA/25, and H3N2-K NY/25 were 200, 231, 119, 50, and 60 at baseline and increased to 582, 661, 356, 85, and 119 at peak immunogenicity, respectively (...), reflecting a significant 2.86- to 2.99-fold increase in NAb titers against the prior H1N1 and H3N2 strains but a lower 1.70- to 1.98-fold increase in NAb titers against the H3N2-K strains . Baseline antibody titers to the H3N2-K strains were 2.0- to 4.6-fold lower than to the prior H1N1 and H3N2 strains (P < .001), and peak antibody titers to the H3N2-K strains following vaccination were 3.0- to 7.8-fold lower than to the prior H1N1 and H3N2 strains (P < .001). (...) Source:  Link:  https://jamanetwork.com/journals/jama/fullarticle/2846268?guestAccessKey=10f1c0a1-4189-438d-9f71-a588fdd0db53&utm_medium=email&utm_source=postup_jn&utm_campaign=article_alert-jama&utm_content=olf-tfl_&utm_term=0309...

  Ann Intern Med SACKS HS In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKD. Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-26-00324. PubMed           Abstract available ANAND R, Glatt AE In healthy adults, a modified RNA vs. inactivated influenza vaccine reduced laboratory-confirmed influenza-like illness at >/=14 d. Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05681. PubMed           Abstract available Antiviral Res RUDRAMURTHY GR, Gudla CS, Harisha R, Selvam V, et al FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo. Antiviral Res. 2026 Mar 2:106382. doi: 10.1016/j.antiviral.2026.106382. PubMed           Abstract available Arch Virol DUTTA M, Sarmah N, Siddique AI, Borah...

  Abstract Wastewater monitoring enables non-invasive, population-scale tracking of community infections independent of healthcare-seeking behavior and clinical diagnosis. Metagenomic sequencing extends this capability by enabling broad, pathogen-agnostic detection, genomic characterization , and identification of novel or unexpected threats . Here, we present data from CASPER (the Coalition for Agnostic Sequencing of Pathogens from Environmental Reservoirs), a U.S.-based wastewater metagenomic sequencing network designed for deep, untargeted pathogen monitoring at national scale. This release includes 1,206 samples collected between December 2023 and December 2025 from 27 sites across nine states , covering 13 million people . Deep sequencing (~1 billion read pairs per sample) generated 1.2 trillion read pairs ( 347 terabases ), enabling detection of even rare taxa , with CASPER representing 66% of all untargeted wastewater sequencing data currently available on the NCBI Sequence ...

  Arch Virol KOBAYASHI D, Hiono T, Adachi R, Igarashi M, et al Length and density of alpha2-3 sialyllactose-containing chains on glycopolymers determine receptor binding of avian influenza viruses. Arch Virol. 2026;171:100. PubMed          PARK SH, Lee SH, Seo YR, Kim DJ, et al Evolution and spread of H8Nx avian influenza viruses from wild birds in East Asia, 2019-2024. Arch Virol. 2026;171:95. PubMed           Abstract available NAVEED A The bovine mammary gland as a crucible for zoonotic influenza virus emergence: Receptor-mediated adaptation of HPAI H5N1 clade 2.3.4.4b. Arch Virol. 2026;171:89. PubMed          Biochem Biophys Res Commun SINGH VA, Nehul S, Saha A, Singh V, et al Bioengineered chimeric VLPs targeting chikungunya virus and SARS-CoV-2 show high immunogenicity in mice. Biochem Biophys Res Commun. 2026;805:153346. PubMed        ...

  February 2026  WHO convenes technical consultations {1} in February and September each year to recommend viruses for inclusion in influenza vaccines {2} for the northern hemisphere (NH) and southern hemisphere (SH) influenza seasons, respectively.  This recommendation relates to the influenza vaccines for use in the NH 2026-2027 influenza season .  A recommendation will be made in September 2026 relating to vaccines that will be used for the SH 2027 influenza season.  WHO guidance for choosing between the NH and SH formulations for countries in tropical and subtropical regions is available on the WHO Global Influenza Programme website {3}.   National or regional authorities approve the composition and formulation of influenza vaccines used in each country.  National public health authorities are responsible for making recommendations regarding the use of the vaccine.  WHO has published recommendations on the prevention of influenza {4}....